Vermilion Receives CE Mark for Overa Test

Austin, Texas-based Vermillion has received CE mark for its Overa test, which detects risk of malignancy for ovarian cancer.

Overa, the next-generation version of the company’s OVA1, is a blood test helping to assess whether a woman with an ovarian adnexal mass is at high or low likelihood of malignancy.

A study of Overa demonstrated specificity of 69 percent, a 28 percent improvement over the first generation test. It also showed an improvement in positive predictive value from 31 percent in OVA1 to 40 percent in Overa.

Vermillion is a bio-analytical solutions firm that aims to help physicians diagnose, treat and improve gynecologic health outcomes for women. — Michael Cipriano